Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1199 results
April 2020
-
Key Release
Novartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützen
Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt im ersten Quartal 2020 um 13% (kWk2, +11% USD) mit zweistelligen Zuwächsen (kWk) bei Innovative Medicines und Sandoz: Zu den… -
Media Release
Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond… -
Media Release
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults… -
Media Release
AveXis Community Statement on the Coronavirus Disease (COVID-19)
Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus disease (COVID-19) and its impact on patients, the SMA… -
Media Release
Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)
New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed… -
Media Release
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial… -
Media Release
Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”
Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline… -
Media Release
Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine
Real-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc… -
Media Release
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus… -
Key Release
Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to…
March 2020
-
Media Release
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified… -
Key Release
Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data1 If approved, Cosentyx would…
Pagination
- ‹ Previous page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- …
- 100
- › Next page
Test disclaimer...!!!